AI Article Synopsis

  • A phase II randomized controlled trial investigated the safety and potential benefits of intracarotid arterial administration (ICAA) of autologous CD34+ cells in patients recovering from acute ischemic stroke (IS) within 14 ± 7 days after the event.
  • Out of 28 patients, those in the cell-treated group showed significant improvement in angiogenesis and better overall recovery scores compared to a control group that received only standard medical therapy.
  • The treatment was found to be 100% safe without any long-term complications, suggesting that ICAA of CD34+ cells could be an effective option for enhancing recovery after IS.

Article Abstract

Background: This phase II randomized controlled trial tested whether the intracarotid arterial administration (ICAA) of autologous CD34 + cells to patients within 14 ± 7 days after acute ischemic stroke (IS) could be safe and further improve short- and long-term outcomes.

Methods: Between January 2018 and March 2022, 28 consecutive patients were equally randomly allocated to the cell-treated group (CD34 + cells/3.0 × 10/patient) or the control group (receiving optimal medical therapy). CD34 + cells were transfused into the ipsilateral brain infarct zone of cell-treated patients via the ICAA in the catheterization room.

Results: The results demonstrated 100% safety and success rates for the procedure, and no long-term tumorigenesis was observed in cell-treated patients. In cell-treated patients, the angiogenesis capacity of circulating endothelial progenitor cells (EPCs)/Matrigel was significantly greater after treatment than before treatment with granulocyte colony-stimulating factor (all p < 0.001). Blood samples from the right internal jugular vein of the cell-treated patients presented significantly greater levels of the stromal cell-derived factor 1α/EPC at 5, 10 and 30 min compared with 0 min (all p < 0.005). The National Institute of Health Stroke Scale scores were similar upon presentation, but a greater response was observed by Days 30 and 90 in the cell-treated group than in the control group. Tc-99 m brain perfusion was significantly greater at 180 days in the cell-treated group than in the control group (p = 0.046). The combined long-term end points (defined as death/recurrent stroke/or severe disability) were notably lower in the control group compared with the cell-treated group (14.3% vs. 50.0%, p = 0.103).

Conclusion: Intracarotid transfusion of autologous CD34 + cells is safe and might improve long-term outcomes in patients with acute IS. Trial registration ISRCTN, ISRCTN15677760. Registered 23 April 2018- Retrospectively registered, https://doi.org/10.1186/ISRCTN15677760.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577584PMC
http://dx.doi.org/10.1186/s13287-024-04021-7DOI Listing

Publication Analysis

Top Keywords

cell-treated patients
12
intracarotid arterial
8
autologous cd34 + cells
8
acute ischemic
8
ischemic stroke
8
patients
5
long term
4
term outcomes
4
outcomes intracarotid
4
arterial transfusion
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!